The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1143
November 11, 2002
View Complete Issue         Table of Contents 2019 
Rasburicase (Elitek) for Hyperuricemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rasburicase (Elitek) for Hyperuricemia
November 11, 2002 (Issue: 1143)
Rasburicase (Elitek - Sanofi-Synthelabo), a recombinant form of urate oxidase derived from the fungus Aspergillus flavus, has been approved by the FDA for intravenous (IV) management of hyperuricemia associated with tumor lysis syndrome in pediatric...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Rasburicase (Elitek) for Hyperuricemia
Article code: 1143b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.